For example, NFIB, the most well studied NFI transcription factor, might be oncogenic in SCLC (Dooley et al., 2011), melanoma, and breast cancer (Fane et al., 2017; Liu et al., 2019), but likely functions as a tumor suppressor in NSCLC (Becker-Santos et al., 2016), osteosarcoma (Mirabello et al., 2015), glioma and glioblastoma (Stringer et al., 2016; Suzuki et al., 2015). Here, NFIB is linked to neoplasm.